Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, Università degli Studi della Campania "Luigi Vanvitelli", Piazza Miraglia, 80138, Naples, Italy. email@example.com.
Department of Internal Medicine, Centre for Liver Diseases, Ospedale Buon Consiglio Fatebenefratelli, Naples, Italy.
Infectious Diseases C.O. Unit, AORN S. Anna and S. Sebastiano, Caserta, Italy.
Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, Università degli Studi della Campania "Luigi Vanvitelli", Piazza Miraglia, 80138, Naples, Italy.
Department of Medical Sciences, AORN S.Anna e S. Sebastiano, Caserta, Italy.
Department of Infectious Emergencies and Infectious Diseases, Azienda Ospedaliera Dei Colli, Naples, Italy.
Department of Diagnostic Service, Azienda Ospedaliera dei Colli, Naples, Italy.
Department of Service, AORN S. Anna and S. Sebastiano, Caserta, Italy.
The aim of this study was to evaluate the effects of antiviral therapy on liver stiffness measurement (LSM).
Two hundred HBV patients were enrolled from four hospital centers in southern Italy; median age was 50.7 (25-75) males were 68%; 171 patients underwent to liver biopsy and 200 patients had LSM at baseline and 189 at the end of follow-up. One hundred and forty-nine patients were treated with nucleos(t)ide analogs, while 51 patients were untreated. The cutoffs of the LSM, related to the fibrosis stages, were as follows: non-advanced fibrosis ≤ 8.1 kPa and advanced fibrosis ≥ 8.2 Kpa.
At baseline, the median value of LSM was 14.1 kPa for advanced fibrosis/cirrhosis and 6.9 kPa for non-advanced fibrosis. LSM was performed at 24 months from the start of therapy. The treated patients (68% received Entecavir and 32% Tenofovir) showed a decrease in liver stiffness measurement of 1.5 kPa (p < 0.001) in non-advanced fibrosis and of 6 kPa (p < 0.001) in advanced fibrosis/cirrhosis. In the patients not undergoing antiviral treatment, no statistically significant change of the LSM was observed (p = 0.26). A logistic binary regression model showed that the only independent factor associated with a significant change in the LSM was the liver stiffness value at baseline (odd ratio 2.855; 95% CI 1.456-5.788; (p = 0.007).
Long-term antiviral therapy induced a significant reduction of liver stiffness measurement and this result may be related to the reduction of liver fibrosis.